Satoru Miura

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 363 citations · Full text

Medicine, Oncology, Pharmacology +17

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

James Chih‐Hsin Yang, Martin Schüler, Sanjay Popat et al. · Journal of Thoracic Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +14

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer

Tateaki Naito, Shuichi Mitsunaga, Satoru Miura et al. · Journal of Cachexia Sarcopenia and Muscle · 2018 · 162 citations · Full text

Medicine, Nutrition, Oncology +17

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 158 citations

Medicine, Oncology, Pharmacotherapy +8

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu et al. · International Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Metastasis +12